RGEN Stock: Price, Earnings History and SEC Filings
Repligen Corporation (RGEN) last traded at $176.94, down 6.20% on the latest session and down 8.0% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.53 against an analyst estimate of $0.46, a beat of 15.2%.
$176.94 -6.20%
1 month-7.95%
52-week high$198.87
52-week low$100.99
Volume4.47M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RGEN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 27, 2026 | $0.53 | $0.46 | +15.22% |
| Jun 2026 | Jul 28, 2026 | $0.54 | $0.45 | +20.00% |
| Mar 2026 | May 5, 2026 | $0.48 | $0.38 | +26.32% |
| Dec 2025 | Feb 24, 2026 | $0.49 | $0.44 | +11.36% |
RGEN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RGEN
SEC filing data is not available right now. You can search for RGEN on SEC EDGAR.
RGEN news
- RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlookNov 1, 2026 · finance.yahoo.com
- 5 must-read analyst questions from Repligen’s Q3 earnings callOct 31, 2026 · finance.yahoo.com
- Repligen Announces $1 Billion Private Convertible Senior Notes TransactionOct 30, 2026 · finance.yahoo.com
- Repligen prices $1B convertible notes due 2031 to refinance 2028 debtOct 30, 2026 · streetinsider.com
- Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic OutlookOct 28, 2026 · finance.yahoo.com
- Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong EarningsOct 28, 2026 · finance.yahoo.com
- Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts GuidanceOct 28, 2026 · finance.yahoo.com
- Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)Oct 27, 2026 · finance.yahoo.com
About Repligen Corporation
Repligen Corporation (RGEN) is a US-listed public company on Nasdaq.